Decreased IL-1ra and NCAM-1/CD56 Serum Levels in Unmedicated Patients with Schizophrenia Before and After Antipsychotic Treatment

키워드

참고문헌 (35)

1. McGrath J, "Schizophrenia: a concise overview of incidence, prevalence, and mortality", Epidemiol Rev, 30, pp.67~76 (2008)[DOI]
2. van Os J, "Schizophrenia", Lancet, 374, pp.635~645 (2009)[DOI]
3. Millier A, "Humanistic burden in schizophrenia: a literature review", J Psychiatr Res, 54, pp.85~93 (2014)[DOI]
4. Howes O, "Glutamate and dopamine in schizophrenia: an update for the 21st century", J Psychopharmacol, 29, pp.97~115 (2015)[DOI]
5. Potvin S, "Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review", Biol Psychiatry, 63, pp.801~808 (2008)[DOI]
6. Upthegrove R, "Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis", Schizophr Res, 155, pp.101~108 (2014)[DOI]
7. Milawaty Nurjono, "A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia", Clinical Psychopharmacology and Neuroscience, 10(2), pp.61~70 (2012), 대한정신약물학회[DOI]
8. Rizos EN, "Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics", World J Biol Psychiatry, 11, pp.251~255 (2010)[DOI]
9. Pillai A, "Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?", Schizophr Res, 193, pp.263~268 (2018)[DOI]
10. Xiao W, "Atypical antipsychotic treatment increases glial cell line-derived neurotrophic factor serum levels in drug-free schizophrenic patients along with improvement of psychotic symptoms and therapeutic effects", Psychiatry Res, 246, pp.617~622 (2016)[DOI]
11. Niitsu T, "Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia", Neurosci Lett, 575, pp.37~41 (2014)[DOI]
12. Martinez-Cengotitabengoa M, "BDNF and NGF signalling in early phases of psychosis: relationship with inflammation and response to antipsychotics after 1 year", Schizophr Bull, 42, pp.142~151 (2016)
13. Petrikis P, "Elevated levels of Insulin-like Growth Factor-1 (IGF-1) in drug-naive patients with psychosis", Psychiatry Res, 246, pp.348~352 (2016)[DOI]
14. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders (5th Ed)" (2013), American Psychiatric Publishing
15. Overall JE, "The brief psychiaric rating scale", Psychol Rep, 10, pp.799~812 (1962)[DOI]
16. Ventura J, "Appendix 1: Brief Psychiatric Rating Scale (BPRS) expanded version (4.0) scales, anchor points and administration manual", Int J Method Psychiatr Res, 3, pp.227~243 (1993)
17. Ruggeri M, "Factor solution of the BPRS-expanded version in schizophrenic outpatients living in five European countries", Schizophr Res, 75, pp.107~117 (2005)[DOI]
18. de Witte L, "Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment", Schizophr Res, 154, pp.23~29 (2014)[DOI]
19. Dinarello CA, "The many worlds of reducing interleukin-1", Arthritis Rheum, 52, pp.1960~1967 (2005)[DOI]
20. Petersen AM, "The anti-inflammatory effect of exercise", J Appl Physiol (1985), 98, pp.1154~1162 (2005)[DOI]
21. Sobis J, "Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity", Pharmacol Rep, 67, pp.353~359 (2015)[DOI]
22. Noto C, "Effects of risperidone on cytokine profile in drug-naive first-episode psychosis", Int J Neuropsychopharmacol, 18 (2014)
23. Cazzullo CL, "Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.33~39 (2002)[DOI]
24. Pae CU, "Antipsychotic treatment may alter T-helper (TH) 2 arm cytokines", Int Immunopharmacol, 6, pp.666~671 (2006)[DOI]
25. Cheng M, "NK cell-based immunotherapy for malignant diseases", Cell Mol Immunol, 10, pp.230~252 (2013)[DOI]
26. Rudolf S, "Search for atypical lymphocytes in schizophrenia", World J Biol Psychiatry, 5, pp.33~37 (2004)[DOI]
27. Steiner J, "Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity", Eur Arch Psychiatry Clin Neurosci, 260, pp.509~518 (2010)[DOI]
28. Miller BJ, "Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects", Biol Psychiatry, 73, pp.993~999 (2013)[DOI]
29. Akanji AO, "Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects", Clin Chem Lab Med, 45, pp.1229~1231 (2007)
30. Autry AE, "Brain-derived neurotrophic factor and neuropsychiatric disorders", Pharmacol Rev, 64, pp.238~258 (2012)[DOI]
31. Silva BA, "A 20-week program of resistance or concurrent exercise improves symptoms of schizophrenia: results of a blind, randomized controlled trial", Rev Bras Psiquiatr, 37, pp.271~279 (2015)[DOI]
32. Martinotti G, "Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review", J Biol Regul Homeost Agents, 26, pp.347~356 (2012)
33. Qin XY, "A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia", Mol Psychiatry, 22, pp.1306~1312 (2017)[DOI]
34. Krivoy A, "Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment", Schizophr Res, 192, pp.226~231 (2018)[DOI]
35. Pirildar S, "Low serum levels of brainderived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.709~713 (2004)[DOI]

관련 논문AI추천